Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya

Julia C Dettinger, John Kinuthia, Jillian Pintye, Felix Abuna, Emily Begnel, Kenneth Mugwanya, Joseph Sila, Harison Lagat, Jared M Baeten, Grace John-Stewart, Julia C Dettinger, John Kinuthia, Jillian Pintye, Felix Abuna, Emily Begnel, Kenneth Mugwanya, Joseph Sila, Harison Lagat, Jared M Baeten, Grace John-Stewart

Abstract

Introduction: The World Health Organization, while recommending pre-exposure prophylaxis (PrEP) for HIV-negative pregnant and postpartum women in HIV high-burden settings, advocates for continued safety evaluation of PrEP in this population.

Methods: The PrEP Implementation in Young Women and Adolescents (PrIYA) program delivered PrEP to pregnant and postpartum women integrated within routine maternal and child health clinics (MCH) at 16 sites in Western Kenya. PrEP exposure and perinatal outcome data were collected among women obtaining postnatal services during programme evaluation. PrEP use was self-reported and confirmed with clinical records. Perinatal outcomes including gestational age at birth, birthweight, congenital malformations and infant growth outcomes were abstracted from clinical records for mother-infant pairs attending the six week visit. Associations between infant outcomes and maternal prenatal PrEP use were assessed using univariate and multivariate logistic and linear regression.

Results: The PrIYA evaluation identified 1530 postpartum mother-infant pairs with data on prenatal PrEP exposure: 206 with prenatal PrEP use, 1324 without. Median maternal age was 24 years in both groups. PrEP users (any reported PrEP use) were significantly more likely to report HIV risk factors such as: intimate partner violence, sexually transmitted infections and having a partner with positive or unknown HIV status. Most mothers initiated PrEP during the second trimester (n = 116, 57%) and used PrEP for more than one month (n = 110, 58%). The mean birthweight was 3.3 kg and gestational age at birth was 38.5 weeks in both groups. There were no major differences between PrEP exposed and unexposed infants in rates of preterm birth and low birthweight. There were no congenital malformations identified in the PrEP-exposed group and five reported in the PrEP unexposed group. At six weeks postpartum, infants in both groups had similar growth. No differences in infant outcomes were found by duration PrEP exposure, trimester of PrEP initiation, a subset analysis of women 15 to 24 years old or in multivariate analyses. This analysis demonstrates that monitoring of infant outcomes is feasible within large-scale programmatic implementation of PrEP among pregnant and postpartum populations.

Conclusions: Pregnancy outcomes and early infant growth did not differ by PrEP exposure.

Keywords: Africa; children; infant; pre-exposure prophylaxis; pregnancy; prevention; women.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1. Flow diagram of inclusion in…
Figure 1. Flow diagram of inclusion in the infant outcomes analysis

References

    1. Vrazo AC, Sullivan D, Ryan Phelps B. Eliminating mother‐to‐child transmission of HIV by 2030: 5 strategies to ensure continued progress. Glob Health Sci Pract. 2018;6(2):249–56.
    1. UNAIDS . AIDSinfo. UNAIDS. [cited 2019 Jan 15]. Available from:
    1. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother‐to‐child transmission of HIV. J Acquir Immune Defic Syndr. 2012;59(4):417–25.
    1. Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4‐8 weeks postpartum in South Africa 2011‐2012: a national population‐based evaluation. PLoS One. 2015;10:e0125525.
    1. Drake AL, Wagner A, Richardson B, John‐Stewart G. Incident HIV during pregnancy and postpartum and risk of mother‐to‐child HIV transmission: a systematic review and meta‐analysis. PLoS Med. 2014;11:e1001608.
    1. Thomson KA, Hughes J, Baeten JM, John‐Stewart G, Celum C, Cohen CR, et al. Increased risk of female hiv‐1 acquisition throughout pregnancy and postpartum: a prospective per‐coital act analysis among women with HIV‐1 infected partners. J Infect Dis. 2018;218(1):16–25.
    1. Humphrey JH, Marinda E, Mutasa K, Moulton LH, Iliff PJ, Ntozini R, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ. 2010;341:c6580.
    1. Njuguna IN, Wagner AD, Cranmer LM, Otieno VO, Onyango JA, Chebet DJ, et al. Hospitalized children reveal health systems gaps in the mother‐child HIV care cascade in Kenya. AIDS Patient Care STDS. 2016;30(3):119–24.
    1. Mofenson LM. Tenofovir pre‐exposure prophylaxis for pregnant and breastfeeding women at risk of HIV infection: the time is now. PLoS Med. 2016;13:e1002133.
    1. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31(2):213–32.
    1. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An empiric HIV risk scoring tool to predict HIV‐1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72(3):333–43.
    1. Damme LV, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
    1. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir‐based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11(1):18–26.
    1. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John‐Stewart G, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312(4):362–71.
    1. Bunge K, Balkus J, Noguchi L, Pan J, Piper J, Marrazzo J, et al. Pregnancy Incidence and Outcomes in Women Receiving Tenofovir‐based PrEP in the VOICE trial. International AIDS Conference; Vancouver, Canada; 2015.
    1. Heffron R, Mugo N, Hong T, Celum C, Marzinke MA, Ngure K, et al. Pregnancy outcomes and infant growth among babies with in‐utero exposure to tenofovir‐based preexposure prophylaxis for HIV prevention. AIDS. 2018;32(12):1707–13.
    1. Pintye J, Baeten JM, Celum C, Mugo N, Ngure K, Were E, et al. Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV‐infected East African women: a prospective study. J Infect Dis. 2017;216(12):1561–8.
    1. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV‐infected women taking long‐term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
    1. Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, et al. Safety of tenofovir disoproxil fumarate‐based antiretroviral therapy regimens in pregnancy for HIV‐infected women and their infants: a systematic review and meta‐analysis. J Acquir Immune Defic Syndr. 2017;76(1):1–12.
    1. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–37.
    1. Siberry GK, Williams PL, Mendez H, Seage GR III, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV‐exposed uninfected infants. AIDS. 2012;26(9):1151–9.
    1. WHO Technical brief . Preventing HIV during pregnancy and breastfeeding in the context of pre‐exposure prophylaxis (PrEP). Geneva, Switzerland: World Health Organization; 2017.
    1. Ministry of Health NASCP . Guidelines on use of Antiretroviral Drugs for Treating and Preventing HIV INfection in Kenya 2016. Nairobi, Kenya: NASCOP; July 2016.
    1. Ministry of Health and Chilcare . Implementation Plan for HIV Pre‐Exposure Prophylaxis in Zimbabwe. Zimbabwe; 2018.
    1. Davies N, Heffron R. Global and national guidance for the use of pre‐exposure prophylaxis during peri‐conception, pregnancy and breastfeeding. Sex Health. 2018;15(6):501–12.
    1. US Public Health Service . Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Center for Disease Control; 2017.
    1. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis. 2017;64(6):751–8.
    1. Kosack CS, de Kieviet W, Bayrak K, Milovic A, Page AL. Evaluation of the Nova StatSensor(R) Xpress(TM) Creatinine point‐of‐care handheld analyzer. PLoS One. 2015;10:e0122433.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
    1. Organization WH . Preterm Birth. Geneva, Switzerland; 2018. [cited 2019 Jan 12]. Available from:
    1. WHO . WHO child growth standards: length/height‐for‐age, weight‐for‐age, weight‐for‐length, weight‐for‐ height and body mass index‐for‐age : methods and development. Geneva, Switzerland: Department of Nutrition for Health and Development; 2006.
    1. Dettinger JC, Kinuthia J, Pintye J, Mwongeli N, Gómez L, Richardson B, et al. PrEP Implementation for Mothers in Antenatal Care (PrIMA): a study protocol of a cluster randomised trial. BMJ Open. 2019;9:e025122.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe